S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
This Stock Could Go Up 66% or More. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:BLTE

Belite Bio (BLTE) Stock Forecast, Price & News

$31.85
0.00 (0.00%)
(As of 09/29/2023 ET)
Compare
Today's Range
$30.50
$31.90
50-Day Range
$17.90
$36.64
52-Week Range
$11.00
$36.70
Volume
33,619 shs
Average Volume
74,289 shs
Market Capitalization
$867.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Belite Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
28.7% Upside
$41.00 Price Target
Short Interest
Healthy
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Belite Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.27) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

302nd out of 972 stocks

Pharmaceutical Preparations Industry

117th out of 444 stocks


BLTE stock logo

About Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

BLTE Price History

BLTE Stock News Headlines

Belite Bio (NASDAQ:BLTE) Trading Down 4.1%
Belite Bio (NASDAQ:BLTE) Stock Price Up 7.9%
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Belite Bio (NASDAQ: BLTE)
Expert Ratings for Belite Bio
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Belite Bio Incorporation American Depository Receipt Repr 1 Sh
The Latest Analyst Ratings for Belite Bio
Why Shares of Belite Bio Soared This Week
Analyst Expectations for Belite Bio's Future
Why Shares of Belite Bio Are Slumping Wednesday
See More Headlines
Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

BLTE Company Calendar

Last Earnings
8/08/2023
Today
9/30/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLTE
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.00
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+28.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.67 per share

Miscellaneous

Free Float
23,610,000
Market Cap
$867.28 million
Optionable
Not Optionable
Beta
-2.10
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Yu-Hsin Lin M.B.A. (Age 44)
    Ph.D., Chairman of Directors & CEO
  • Mr. Hao-Yuan Chuang C.F.A. (Age 39)
    F.R.M., M.B.A., CFO & Director
  • Dr. Nathan L. Mata Ph.D. (Age 57)
    Chief Scientific Officer













BLTE Stock - Frequently Asked Questions

Should I buy or sell Belite Bio stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLTE shares.
View BLTE analyst ratings
or view top-rated stocks.

What is Belite Bio's stock price forecast for 2023?

6 equities research analysts have issued 12-month price objectives for Belite Bio's shares. Their BLTE share price forecasts range from $25.00 to $57.00. On average, they expect the company's stock price to reach $41.00 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price.
View analysts price targets for BLTE
or view top-rated stocks among Wall Street analysts.

How have BLTE shares performed in 2023?

Belite Bio's stock was trading at $30.1450 on January 1st, 2023. Since then, BLTE shares have increased by 5.7% and is now trading at $31.85.
View the best growth stocks for 2023 here
.

Are investors shorting Belite Bio?

Belite Bio saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 44,200 shares, an increase of 17.9% from the August 31st total of 37,500 shares. Based on an average daily trading volume, of 83,500 shares, the days-to-cover ratio is currently 0.5 days.
View Belite Bio's Short Interest
.

When is Belite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our BLTE earnings forecast
.

How were Belite Bio's earnings last quarter?

Belite Bio, Inc (NASDAQ:BLTE) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.03.

When did Belite Bio IPO?

(BLTE) raised $36 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.

What is Belite Bio's stock symbol?

Belite Bio trades on the NASDAQ under the ticker symbol "BLTE."

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Belite Bio's stock price today?

One share of BLTE stock can currently be purchased for approximately $31.85.

How much money does Belite Bio make?

Belite Bio (NASDAQ:BLTE) has a market capitalization of $867.28 million.

How can I contact Belite Bio?

The official website for the company is belitebio.com. The company can be reached via phone at 858-246-6240 or via email at ir@belitebio.com.

This page (NASDAQ:BLTE) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -